# Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Source: https://onco.cc/trials/nct05386108/  
OnCo record `nct05386108` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Elacestrant and Abemaciclib in brain and spinal cord tumours, run by Stemline Therapeutics, Inc., now recruiting.

## Summary

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer is a phase 1/2 interventional study registered as NCT05386108 by Stemline Therapeutics, Inc., with 73 participants planned, started 2022-08-31 and due to reach its primary completion in 2026-12. Interventions recorded: Elacestrant and Abemaciclib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05386108
- Phase: 1/2
- Setting: An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer
- Sponsor: Stemline Therapeutics, Inc.
- Enrolled: 73

## Sources

- ClinicalTrials.gov NCT05386108: https://clinicaltrials.gov/study/NCT05386108

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Elacestrant](https://onco.cc/drugs/elacestrant/)
- companies: [Menarini / Stemline](https://onco.cc/companies/menarini/)

---
JSON: https://onco.cc/api/v1/entities/nct05386108.json